10-K: Scientific Industries Reports Full Year 2023 Results, Focuses on Bioprocessing Growth

Scientific Industries, Inc. reported its full year 2023 results, highlighting a slight revenue increase and ongoing investments in its bioprocessing segment despite continued losses.

Summary

• Scientific Industries, Inc. reported a net loss of $9.09 million for the year ended December 31, 2023, compared to a net loss of $15.64 million for the prior year.
• The company's total net revenues increased slightly by 2.1% to $11.11 million in 2023.
• Benchtop Laboratory Equipment sales saw a mixed performance, with Torbal division products increasing to $3.66 million, while Vortex-Genie product sales decreased to $3.55 million.
• Bioprocessing Systems product sales contributed to the revenue increase, driven by the Cell Growth Quantifier (CGQ) and Liquid Injection System (LIS).
• The gross profit percentage decreased to 45.9% in 2023 from 47.2% in 2022, due to increased material and labor costs.
• Research and development expenses increased by 29.6% to $3.57 million, primarily due to the development of the DOTS platform and VIVID pill counter products.
• The company raised $6.28 million in equity financing during the fourth quarter of 2023 and an additional $716,776 in January 2024.
• The company has a working line of credit of $300,000 with its primary bank.

Sentiment

Score: 4

Explanation: The document presents a mixed picture with some positive developments like increased sales in certain segments and successful capital raising, but the overall sentiment is negative due to continued losses, decreased gross profit, and the need for further funding. The company is facing significant challenges in its bioprocessing segment.

Positives

• The company's net loss decreased from $15.64 million in 2022 to $9.09 million in 2023.
• Sales of Torbal division products increased, driven by the VIVID automated pill counter.
• The company successfully raised additional capital through equity financing.
• The company is actively managing costs and streamlining operations.

Negatives

• The company experienced a net loss of $9.09 million for the year ended December 31, 2023.
• The gross profit percentage decreased to 45.9% from 47.2% in the prior year.
• The company's cash and cash equivalents decreased by $1.13 million to $796,100 as of December 31, 2023.
• The company has an accumulated deficit of $27.49 million as of December 31, 2023.

Risks

• The company has limited financial resources and may need to raise additional funding.
• The company has a history of losses and will likely incur future losses.
• The commercial success of the bioprocessing products depends on market acceptance.
• The company relies on key management personnel and may not be able to execute its business strategy effectively if they leave.
• The company is exposed to foreign exchange rate risk.
• The company is dependent on outside suppliers for components of its products.
• The company has limited patent protection for some of its products.

Future Outlook

The company expects that research and development expenditures in the fiscal year ending December 31, 2024 will continue to be material reflecting continued product development efforts for the Bioprocessing Systems operations and, to a lesser extent, continued investment in new VIVID pill counting products.

Management Comments

• Management believes that the strategic initiatives undertaken will provide sufficient funding to enable the Company to continue to operate as a going concern.
• Management is continuing to evaluate additional cost measures, that includes reductions in operation headcounts to continue to operate as a going concern.

Industry Context

The company operates in the competitive laboratory equipment and bioprocessing industries, facing competition from larger companies with greater resources. The bioprocessing market is relatively new and subject to rapid innovation, requiring continuous investment in product development.

Comparison to Industry Standards

• The company's Benchtop Laboratory Equipment segment competes with companies like Henry Troemner, IKA-Werke, Benchmark Scientific, and Heidolph Instruments, which are generally larger and have greater resources.
• The Torbal brand competes with Ohaus Corporation, A&D Company Ltd., Adam Equipment Co., Ltd., Avery Weigh-Tronix, and Capsa Healthcare.
• The Bioprocessing Systems segment competes with ABER Instruments and PreSens GmbH, as well as larger solution providers like Sartorius AG and Eppendorf SE.
• The company's sales of $11.11 million are significantly lower than many of its competitors in the industry.

Related Party Transactions

• The company's consulting agreement with Mr. Joseph G. Cremonese, a Director of the Company, and his affiliate which provided consulting services on product development, expired on December 31, 2021.
• The company's consulting agreement with Mr. Reinhard Vogt, a former Director of the Company, and his affiliate which provided consulting services was terminated on April 1, 2022.

Stakeholder Impact

• Shareholders face the risk of dilution due to potential future capital raises.
• Employees may be affected by potential cost-cutting measures, including reductions in headcount.
• Customers may benefit from the company's continued investment in product development.
• Suppliers may be impacted by the company's financial performance and potential cost-cutting measures.

Next Steps

• The company will continue to evaluate additional cost measures, including reductions in operation headcounts.
• The company will continue to invest in product development for the Bioprocessing Systems operations and the VIVID pill counter products.

Key Dates

Keywords

bioprocessing, laboratory equipment, financial results, equity financing, research and development, Vortex-Genie, Torbal, DOTS, net loss, revenue